Tag Archives: Immunotherapy for Cancer

NIH Calls Proposed Cancer Research Funding Cuts Unacceptable

NIH Calls Proposed Cancer Research Funding Cuts Unacceptable
NIH Calls Proposed Cancer Research Funding Cuts Unacceptable

Can you put a price on good health? Major medical organizations have been reacting strongly to proposed deep cuts in scientific and medical research funding that would severely hamper research programs such as immunotherapy for cancer.

Drastic Slashes in Scientific Research Funding and Healthcare Coverage

Stipulations in the Trump administration’s proposed 2018 budget that are drawing the biggest backlash include:

• The National Institutes of Health (NIH) would see a staggering $5.8 billion reduction in overall funding, of which $1 billion would come out of the budget for the National Cancer Institute (NCI).

• Over the next 10 years Medicaid funding would be reduced by $600 billion, resulting in lack of health insurance for needy groups such as children, elderly and disabled.

The Scientific and Medical Community Responds

Daniel F. Hayes, M.D., president of the American Society of Clinical Oncology (ASCO), explained that many major breakthroughs in cancer research have come from federally-funded organizations such as the NIH. In addition, federal research funding allows the scientific and medical industry to generate $60 billion a year in economic activity.

Similar concern was expressed by Chris Hansen, president of the American Cancer Society’s Cancer Action Network (ACS CAN). He referred to polls showing that 90 percent of voters rate federal funding for medical research as “very” or “extremely” important, with 75 percent supporting an increase in NIH funding.

Building on the Issels® Legacy

Our immunotherapy for cancer clinic has carried on the high standards and innovative programs of our founder, Josef M. Issels. Contact us to learn more about our personally tailored, state-of-the-art treatments such as cancer vaccines and NK cells.

June is Cancer Immunotherapy Month

June is Cancer Immunotherapy Awareness Month
June is Cancer Immunotherapy Awareness Month

In the fight against cancer, immunotherapy has been a game-changer. The Society of Immunotherapy for Cancer (SITC) is recognizing June as Cancer Immunotherapy Month to recognize and promote the value of these treatments.

Putting Immunotherapy in the Public Eye

The SITC observes Cancer Immunotherapy Month by promoting public awareness of immunotherapy and sponsoring educational events for both healthcare professionals and patients.

Here are a few of the programs scheduled for the upcoming month:

• “Cancer Immunity and Immunotherapy” is being held as part of the annual meeting of the Federation of Clinical Immunology Societies. Presentations will focus on tumor immunology and therapies such as vaccines, CAR-T cells and checkpoint inhibitors.

• “Incorporating Radiation Oncology into Immunotherapy” is a two-day workshop exploring the challenges and opportunities of combining the different methods into one integrative treatment.

• “Rational Combinations 360º” is a comprehensive examination of combining therapies as it relates to business, clinical and scientific aspects.

How Can You Participate?

Everyone has been touched by cancer in one way or another. There are a number of ways you can support Cancer Immunotherapy Month.

• Join the Cancer Immunotherapy CONNECT Open Forum and share your stories with other members.

• Purchase a SITC Cure t-shirt.

• Post your support of immunotherapy for cancer research on Twitter, Facebook and other social media platforms.

• Donate to the Forward Fund for immunotherapy research.

State-of-the-Art Immunotherapy for Cancer at Issels®

Our founder, Dr. Josef M. Issels, was a pioneer in the development and use of immunotherapy. Visit our website for more information about Dr. Issels and our individually tailored non-toxic immunotherapy programs.

The Cost of Some New Cancer Drugs Spiral Out of Reach for Some Patients

The Cost of Some Medications Is Rising
The Cost of Some Medications Is Rising

The last few years have brought exciting advances in immunotherapy for cancer, but innovation has come at a price … literally. Skyrocketing costs for cancer drugs are making them inaccessible for many who would benefit the most.

Cancer Drugs: The Price of Success

During the 10-year period between 2005 and 2015, Big Pharma’s pipeline of cancer drugs increased by 63 percent, with several reaching the market. As a result, the global market is projected to grow from $16.9 billion in 2015 to an astounding $75.8 billion in 2022.

But while competition generally serves to drive prices down, that’s not happening with the new cancer drugs. Factors such as market exclusivity, insurance plan structures and lack of head-to-head comparison studies combine to keep prices high.

One example is checkpoint inhibitors, which release the systemic “brakes” preventing the immune system from recognizing and attacking cancer cells. Bristol, Merck, Roche and Pfizer all have checkpoint inhibitors on the market, but each has an annual price tag approaching $150,000.

What’s the Answer?

Experts see no evidence that pharmaceutical companies, driven by the current free rein on pricing, are exploring more cost-effective solutions. President Donald Trump and lawmakers from both parties are prioritizing a search for methods to restrain spiraling cancer drug costs, ranging from more price negotiation to faster approval.

Issels® Leads the Field in Immunotherapy for Cancer

While the medical community and lawmakers grapple with the finances of immunotherapy for cancer, we have been successfully treating patients with individually developed non-toxic protocols for years. Contact us today to learn more about cancer vaccines, NK cells and other immunotherapy programs at Issels®.

Transformative Impact of Immunotherapy Tops Cancer News

Diverse Hands Holding The Word Cancer
Immunotherapy brings breakthroughs to cancer treatment.

For decades, cancer has been the main focus of innumerable medical researchers. During 2016, immunotherapy for cancer was designated the top advance in the field for the second consecutive year.

The Rapid Rise of Immunotherapy Treatment

The announcement was made in Clinical Cancer Advances 2017, the 12th annual report from the American Society of Clinical Oncology (ASCO). Dr. Daniel F. Hayes, president of ASCO, presented the report to Congress during a recent meeting to request continued funding for cancer research.

According to Dr. Hayes, immunotherapy was a “promising theoretical treatment” less than 10 years ago. In a relatively short span of time, it has become a “standard of care” that has positively affected thousands of patients.

“Immunotherapy 2.0”

Just how much progress has been made in immunotherapy for cancer? Since 2011, a total of 15 immune-targeted therapies have been approved. That success combined with continued improvements in identifying candidates and overcoming resistance mechanisms, led ASCO to dub it “Immunotherapy 2.0.”

Dr. Hayes also stressed the importance of federal funding in maintaining the momentum in cancer research. One prominent development that has made a significant impact is the Cancer Moonshot program. Former Vice President Joe Biden took up the cause after his son Beau’s death from brain cancer.

Issels®: Ahead of the Curve

While the rest of the medical community is embracing the value of immunotherapy for cancer, we have been in the forefront of successfully treating patients by boosting their own immune systems. Visit our website to learn more about cancer vaccines, NK cells and our other non-toxic, individually tailored programs.

 

Is There a Link Between Gut Bacteria and an Immunotherapy Response?

Questions on How Immunotherapy Will Work for You?
Questions on How Immunotherapy Will Work for You?

Could the path to fighting cancer go through your stomach? Researchers have found a surprising link between immunotherapy for cancer and the bacteria found in your gut.

The Varied Responses to Immunotherapy

While scientists had previously made the connection with mice, a team at the University of Texas MD Anderson Cancer Center recently made a breakthrough with the first study involving humans. The subjects included 233 patients with advanced melanoma.

A subset of 43 patients was on checkpoint inhibitors, one of the primary methods of immunotherapy for cancer. Out of this group, 30 responded to the treatment while 13 did not.

What made the difference? The researchers discovered that the 30 patients who responded had a wider variety of gut bacteria, particularly a specific type called Clostridiales, along with a higher concentration of the immune cells that fight cancer.

Strengthening the Immune System

According to Fred Ramsdell, vice president of research at the Parker Institute for Cancer Immunotherapy, it’s likely that exposure to a greater amount of bacteria during your lifetime results in a more robust immune system. Exactly why this happens is still a puzzle for now.

Experts are optimistic that this information will eventually be used to more effectively target patients who will respond to immunotherapy treatments. A clinical trial focusing on the microbiome is planned for later this year.

Immunotherapy for Cancer: The Issels® Approach

Our namesake, Dr. Josef M. Issels, pioneered non-toxic immunotherapy treatments and we carry on his legacy today. Contact us for more information about our individually tailored programs that are created to meet your individual needs.

Immunotherapy Trains Your Body to Fight Its Own Cancer

Immunotherapy Trains Your Body to Fight Its Own Cancer
Immunotherapy Trains Your Body to Fight Its Own Cancer

Your body’s immune system does an amazing job of protecting you from viruses, bacteria and other invaders. Tumor cells are able to avoid detection as foreign bodies, but immunotherapy for cancer is removing this advantage by boosting your body’s natural defenses.

How Cancer “Hijacks” the Immune System

When foreign cells invade your body, they carry proteins called antigens that trigger an immune response. Your system produces antibodies that bind with the antigens, which either neutralize the rogue cells on their own or alert T-cells to attack and destroy them.

While cancer cells also produce antigens, they manage to evade the normal process by hijacking the checkpoints that signal the immune system to attack. The cells remain undetected, allowing them to multiply as they continue to weaken the immune system.

Penetrating the Shield around Cancer Cells

Instead of using external treatments like radiation and chemotherapy to fight tumors, immunotherapy for cancer focuses on boosting the natural abilities of the immune system by “training” it to recognize and attack cancer cells. These methods include:

  • Drugs containing lab-made monoclonal antibodies that bind to cancer cell antigens and block the normal proteins that “disguise” them
  • Vaccines containing proteins that help the immune system recognize antigens on tumor cells

Issels®: A Personalized Approach

Immunotherapy for cancer has become a valuable alternative or supplement to traditional treatments, but each patient’s case is different. We use specialized testing to create an integrative treatment method that addresses your particular needs.

Contact us today to learn why Issels® has been a leader in the successful use of immunotherapy treatments.